New Stock News | HuGe Embarks on Listing in Hong Kong Stock Exchange As the Largest Manufacturer of Dental Clinical Materials in China

According to the disclosure of the Hong Kong Stock Exchange on February 18th, Huge Dental Limited (referred to as "Shanghai Dove") submitted an application to the main board of the Hong Kong Stock Exchange, with CICC and DBS as the joint sponsors. According to the prospectus, Shanghai Dove is one of the leading domestic manufacturers of dental materials in China, offering a diverse product portfolio covering dental clinical products, dental laboratory products, and digital dental products, suitable for various application scenarios in the core dental professional fields. The company's comprehensive product matrix covers all scenarios of dental medical institutions (including dental hospitals and clinics) and dental laboratories, effectively meeting the diverse clinical needs of customers including those in restorative dentistry, implantology, endodontics, orthodontics, and pediatric dentistry. According to Frost & Sullivan's data, based on 2023 sales revenue, Shanghai Dove is the largest manufacturer of dental impression materials in China, and is also one of the largest manufacturers of dental clinical materials in China, with the most CE-marked or FDA-approved dental clinical materials among domestic manufacturers. In China, Shanghai Dove provides services to a large number of dental medical institutions and is supported by a large network of distributors and dental laboratories. In overseas markets, Shanghai Dove's products have obtained certifications in more than 60 countries and regions. The company's main overseas markets include Europe, the United States, and Southeast Asia. The company is competitive in both the European and American markets, and is aiming to become a leader in the Southeast Asian market. Through extensive market development, Shanghai Dove's brands (such as Shanghai Dove, Hulushu, Kaijing, Kaifeng, Kaili, Kaibiao, Mejia Yin, Meiyiting, Meijingci, Huluge Mei Yue, Meitiangu, and VinciSmile) have gained significant visibility in the dental medical equipment industry and have earned a good market reputation. Financially, for the nine months ending on September 30 of 2022, 2023, and 2024, Shanghai Dove's revenues were approximately 280 million, 358 million, and 304 million RMB respectively; during the same period, the annual profits were 64.033 million, 88.354 million, and 77.708 million RMB respectively.